[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343253-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-343253-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","sugt1-regulates-the-progression-of-ovarian-cancer-through-the-aktpi3k-mtor-signaling-pathway","SUGT1 regulates the progression of ovarian cancer through the AKT/PI3K/ mTOR signaling pathway","","This study investigates the expression and functional roles of SUGT1 in ovarian cancer, utilizing data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) projects. Analyses show SUGT1 is significantly upregulated in ovarian cancer tissues and higher expression associates with worse patient outcomes. Functional effects were tested using in vitro and in vivo experiments, with Gene Set Enrichment Analysis linking SUGT1 to activated glycolytic pathways. SUGT1 inhibition reduces proliferation, invasion, and migration while increasing apoptosis. The transcription factor ELF1 is identified as a direct regulator of SUGT1 via promoter analysis and chromatin immunoprecipitation, suggesting biomarker and therapeutic potential.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/sugt1-regulates-the-progression-of-ovarian-cancer-through-the-aktpi3k-mtor-signaling-pathway/343253/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/sugt1-regulates-the-progression-of-ovarian-cancer-through-the-aktpi3k-mtor-signaling-pathway/343253.png","ImageObject",300,407,{"name":42,"@type":43},"Miles","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":33},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"How is SUGT1 expression related to ovarian cancer outcomes?","Question",{"text":62,"@type":63},"SUGT1 is upregulated in ovarian cancer tissues compared with normal controls, and elevated SUGT1 expression correlates with poorer patient outcomes.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"What evidence links SUGT1 to metabolic reprogramming in ovarian cancer?",{"text":67,"@type":63},"Gene Set Enrichment Analysis shows high SUGT1 expression is associated with activation of glycolytic pathways, indicating a role in metabolic reprogramming.",{"name":69,"@type":60,"acceptedAnswer":70},"What happens to ovarian cancer cells when SUGT1 is inhibited?",{"text":71,"@type":63},"In ovarian cancer cell lines, SUGT1 knockdown via siRNA decreases proliferation and increases apoptosis, and it also reduces migration and invasion capabilities.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},343253,1792315589,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":33,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Translational Oncology 49 (2024) 102088  \nContents lists available at ScienceDirect  \nTranslational Oncology  \njournal [homepage:](homepage: www.elsevier.com/locate/tranon)[ www.elsevier.com/locate/tranon](homepage: www.elsevier.com/locate/tranon)  \n| SUGT1 regulates the progression of ovarian cancer through the AKT/PI3K/ mTOR signaling pathway\u003Cbr>Miao Kea, 1 , Jie Xub, 1 , Ye Ouyang c, 1 , Junyu Chend , Donglan Yuan e, * , Ting Guob, *\u003Cbr>a Department of Gynecology and Obstetrics, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China\u003Cbr>b Institute of Clinical Medicine, The Affiliated Taizhou People’s Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, China\u003Cbr>c Graduate Management Department, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong Province, China\u003Cbr>d School of Nursing, Nanjing University of Chinese Medicine, Nanjing, China\u003Cbr>e Department of Gynecology and Obstetrics, The Affiliated Taizhou People’s Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, China |  |  |\n| --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |\n| Keywords: SUGT1\u003Cbr>Ovarian cancer\u003Cbr>Bioinformatics Animal Glycolytic |  | This study investigates the expression and functional roles of SUGT1 in ovarian cancer, utilizing data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) projects. Our analyses reveal that SUGT1 is significantly upregulated in ovarian cancer tissues compared to normal controls. We further explore the prognostic value of SUGT1, where elevated expression correlates with poorer patient outcomes, particularly in ovarian cancer. The functional implications of SUGT1 in cancer biology were assessed through in vitro and in vivo experiments. Gene Set Enrichment Analysis (GSEA) indicates a significant association between high SUGT1 expression and the activation of glycolytic pathways, suggesting a potential role in metabolic reprogramming. Inhibition of SUGT1 via siRNA in ovarian cancer cell lines results in decreased proliferation and increased apoptosis, along with reduced migration and invasion capabilities. Additionally, our study identifies the transcription factor ELF1 as a significant regulator of SUGT1 expression. Through promoter analysis and chromatin immunoprecipitation, we demonstrate that ELF1 directly binds to the SUGT1 promoter, enhancing its transcription. This regulatory mechanism underscores the importance of transcriptional control in cancer metabolism, providing insights into potential therapeutic targets. Our findings establish SUGT1 as a crucial player in the oncogenic processes of ovarian cancer, influencing both metabolic pathways and transcriptional regulation. This highlights its potential as a biomarker and therapeutic target in managing ovarian cancer. |\n\nIntroduction  \nSUGT1, an MIS12 kinetochore complex assembly cochaperone, is responsible for encoding a highly conserved protein involved in the centromere assembly process [1]. SUGT1 acts as a chaperone for the Hsp90 protein and ensures efficient microtubule binding site formation by recruiting the MIS12 complex to the kinetochore [2]. Current studies have shown that SUGT1-involved mitomere assembly is involved in a variety of pathophysiological processes in mammals and humans. SUGT1 is thought to be a protective factor for HIV-1 infection since it increases HIV susceptibility by stabilizing microtubule plus-ends and controls the vulnerability of lymphocyte and macrophage infiltration by controlling the nuclear import of the viral DNA [3]. In addition, there  \nare several studies demonstrating the specific role of SUGT1 in tumors. SUGT1 is a significant positive regulator of MHC-I and MHC-II cell surface expression and plays a crucial role in controlling the immune system’s surveillance activity against lymphoma, according to Devin Dersh et al. [4]. In","cbCaimB0axHsxoRC","https://ap.wps.com/l/cbCaimB0axHsxoRC","pdf",13736736,14,"English","# Introduction\n# Materials and methods\n## SUGT1 expression in tumor tissues, normal tissues, and cell lines\n## Investigation of the diagnostic and prognostic potential of SUGT1","[{\"question\":\"How is SUGT1 expression related to ovarian cancer outcomes?\",\"answer\":\"SUGT1 is upregulated in ovarian cancer tissues compared with normal controls, and elevated SUGT1 expression correlates with poorer patient outcomes.\"},{\"question\":\"What evidence links SUGT1 to metabolic reprogramming in ovarian cancer?\",\"answer\":\"Gene Set Enrichment Analysis shows high SUGT1 expression is associated with activation of glycolytic pathways, indicating a role in metabolic reprogramming.\"},{\"question\":\"What happens to ovarian cancer cells when SUGT1 is inhibited?\",\"answer\":\"In ovarian cancer cell lines, SUGT1 knockdown via siRNA decreases proliferation and increases apoptosis, and it also reduces migration and invasion capabilities.\"}]","SUGT1 regulates the progression of ovarian cancer through the AKT/PI3K/ mTOR signaling pathway | PDF",1790050432,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2dcb650ddf4226f6d5c355e1e938dddb.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a70bbc3ac054113c45ff93b21d651c60.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/361d4b1f0373b6441a719e51594c5d0f.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b160cb1ce91c0dfc5538d4e6d2dbcd27.webp",980,1306]